Hong Kong's innovative pharmaceutical sector started to decline in early trading, with Gilead Sciences-B falling by more than 8%.

In the early trading session, the Hong Kong stock market's biopharmaceutical sector trended lower, with Gilead Sciences plunging over 8%, BeiGene dropping over 7%, CSPC Pharmaceutical Group falling over 5%,and Innovent Biologics, Rongchang Biotech, and Junshi Biosciences all declining.